Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

NCT00129740 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myelogenous, Chronic

Interventions

DRUG: Nilotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]